Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
740
Trial Sponsor
Clinical Trial Start Date
2012
0Primary Completion Date
2012
0Study Completion Date
2012
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Interventional Trial Phase
Phase 10
Official Name
A Multi-Center, Double Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of EBI-005 Ophthalmic Solution Versus Placebo in Subjects With Dry Eye Syndrome0
Last Updated
August 14, 2013
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Quadruple0
Masked Party
Outcomes Assessor0
Investigator0
Care Provider0
Participant0
Other attributes
Intervention Treatment
EBI-005-20
Study summary
This is a Phase 1b, multi-center, double-masked, randomized, placebo-controlled, parallel-group study designed to evaluate the safety and biological activity of two doses of EBI-005 ophthalmic solution versus placebo in subjects with moderate to severe Dry Eye Syndrome. Approximately 72 subjects will be enrolled and randomized in this study at up to 9 centers located in the United States (US). Subjects will be enrolled in two groups or cohorts. The first enrollment group will consist of 33 subjects.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
